Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-05-31 AGM Information
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document explicitly states it is a 'Bulletin from the Annual General Meeting in Oncopeptides AB (publ)' held on May 31, 2024. It details the principal resolutions passed, including the adoption of the annual report, approval of remuneration, re-election of board members, and the introduction of new shareholder programs (Board SHP 2024 and Co-worker LTIP 2024). These resolutions and the context of the meeting directly correspond to the information presented during or immediately following an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2024-05-31 English
Kommuniké från årsstämma i Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is titled 'Kommuniké från årsstämma i Oncopeptides AB (publ)' which translates to 'Communiqué from the Annual General Meeting of Oncopeptides AB (publ)'. The text details the main decisions made at the AGM held on May 31, 2024, including the approval of the annual report, election of board members, approval of remuneration, and the establishment of new long-term incentive programs (Board SHP 2024 and Co-worker LTIP 2024). These contents are characteristic of materials presented or summarized immediately following an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2024-05-31 Swedish
Number of shares and votes in Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing a change in the number of shares and votes in Oncopeptides following a rights issue. This falls under the category of capital changes and share issuance updates. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the appropriate classification for announcements regarding new share issues or capital changes.
2024-05-31 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement (under 5,000 characters) regarding a change in the total number of shares and votes in Oncopeptides following a rights issue. It explicitly mentions the change in share capital and total voting rights, which is a standard regulatory disclosure for capital changes. While it relates to share capital, it is a formal notification of the current status of shares and votes rather than a primary document for a new share issuance or a buyback program. Given the nature of the disclosure regarding share counts and voting rights, it fits best under 'Share Issue/Capital Change' (SHA).
2024-05-31 Swedish
Oncopeptides emitterar teckningsoptioner för att uppfylla sina skyldigheter under låneavtal med EIB
Capital/Financing Update Classification · 1% confidence The document text describes a decision by Oncopeptides AB to issue warrants (teckningsoptioner) to the European Investment Bank (EIB) to fulfill obligations under a loan agreement. This action directly relates to changes in the company's capital structure, financing arrangements, and the issuance of new securities (warrants). This aligns best with the 'Capital/Financing Update' category (CAP). Although it involves warrants, it is a specific financing obligation fulfillment rather than a general share issue (SHA) or a transaction in own shares (POS). The document is a formal announcement detailing the terms and purpose of this issuance.
2024-05-30 Swedish
Oncopeptides issues warrants to fulfil its obligations under loan agreement with EIB
Share Issue/Capital Change Classification · 1% confidence The document announces that Oncopeptides has resolved to issue warrants to fulfill obligations under a loan agreement with the EIB. This action involves the issuance of new securities (warrants) which will lead to an increase in share capital upon subscription. This directly relates to changes in the company's capital structure and financing arrangements. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate category, as it covers fundraising, financing activities, or capital structure changes. Although it involves warrants, it is not a general share issue announcement (SHA) but a specific financing obligation fulfillment. It is not a standard regulatory filing (RNS) because it fits a more specific category (CAP). The document length is relatively short (3962 chars) and appears to be a press release announcing the action, not the detailed legal filing itself, but the content is substantive enough to classify it as the event announcement rather than just an RPA.
2024-05-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.